The MS Market Boom: A Catalyst for Novartis' Growth? The recent Phase 3 trial results for remibrutinib, Novartis' newly touted multiple sclerosis (MS) treatment, have sent shockwaves through the pharmaceutical industry.
Estimated peak annual sales in MS alone could reach $3 billion, and potentially more than $10 billion across all indications. The global MS therapeutics market is expected to grow at a 5.
9% compound annual growth rate, reaching approximately $38. 6 billion by 2030. Novartis already has a significant presence in this space through its established MS drug Kesimpta, which generated $1.